Which drug first? study seeks optimal sequence for neuroendocrine tumor therapy
NCT ID NCT07534371
First seen Apr 21, 2026 · Last updated May 21, 2026 · Updated 4 times
Summary
This study looks at 500 people with advanced neuroendocrine tumors to see which order of two treatments works best: starting with surufatinib then somatostatin analogs, or the reverse. Researchers will track how long the cancer stays under control and any side effects. The goal is to help doctors choose the best treatment sequence for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.